1. Home
  2. GORO vs BMEA Comparison

GORO vs BMEA Comparison

Compare GORO & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gold Resource Corporation

GORO

Gold Resource Corporation

N/A

Current Price

$1.44

Market Cap

250.9M

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.50

Market Cap

90.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GORO
BMEA
Founded
1998
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.9M
90.5M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
GORO
BMEA
Price
$1.44
$1.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$1.75
$8.71
AVG Volume (30 Days)
2.2M
804.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$65,726,000.00
N/A
Revenue This Year
$9.04
N/A
Revenue Next Year
$93.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.87
52 Week High
$1.87
$3.08

Technical Indicators

Market Signals
Indicator
GORO
BMEA
Relative Strength Index (RSI) 48.44 61.14
Support Level $1.27 $1.24
Resistance Level $1.75 $1.56
Average True Range (ATR) 0.10 0.09
MACD -0.03 0.01
Stochastic Oscillator 28.00 85.19

Price Performance

Historical Comparison
GORO
BMEA

About GORO Gold Resource Corporation

Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: